352 related articles for article (PubMed ID: 23974768)
1. New medications for obesity management: changing the landscape of obesity treatment.
Boulghassoul-Pietrzykowska N; Franceschelli J; Still C
Curr Opin Endocrinol Diabetes Obes; 2013 Oct; 20(5):407-11. PubMed ID: 23974768
[TBL] [Abstract][Full Text] [Related]
2. Obesity Pharmacotherapy.
Saunders KH; Umashanker D; Igel LI; Kumar RB; Aronne LJ
Med Clin North Am; 2018 Jan; 102(1):135-148. PubMed ID: 29156182
[TBL] [Abstract][Full Text] [Related]
3. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
4. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
5. Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Bays H
Expert Rev Cardiovasc Ther; 2010 Dec; 8(12):1777-801. PubMed ID: 20707765
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of medications approved for chronic weight management.
Fujioka K
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S7-11. PubMed ID: 25900872
[TBL] [Abstract][Full Text] [Related]
7. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.
Khera R; Murad MH; Chandar AK; Dulai PS; Wang Z; Prokop LJ; Loomba R; Camilleri M; Singh S
JAMA; 2016 Jun; 315(22):2424-34. PubMed ID: 27299618
[TBL] [Abstract][Full Text] [Related]
8. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
9. Safety assessment of combination therapies in the treatment of obesity: focus on naltrexone/bupropion extended release and phentermine-topiramate extended release.
Halpern B; Mancini MC
Expert Opin Drug Saf; 2017 Jan; 16(1):27-39. PubMed ID: 27732121
[TBL] [Abstract][Full Text] [Related]
10. Treatment of obesity in 2015.
Shukla AP; Buniak WI; Aronne LJ
J Cardiopulm Rehabil Prev; 2015; 35(2):81-92. PubMed ID: 25714749
[TBL] [Abstract][Full Text] [Related]
11. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
12. A review of the metabolic effects of controlled-release Phentermine/Topiramate.
Kiortsis DN
Hormones (Athens); 2013; 12(4):507-16. PubMed ID: 24457398
[TBL] [Abstract][Full Text] [Related]
13. Obesity consults--comprehensive obesity management in 2013: understanding the shifting paradigm.
Kushner RF; Apovian CM; Fujioka K
Obesity (Silver Spring); 2013 Nov; 21 Suppl 2():S3-13; quiz S14-5. PubMed ID: 24259347
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Tak YJ; Lee SY
Curr Obes Rep; 2021 Mar; 10(1):14-30. PubMed ID: 33410104
[TBL] [Abstract][Full Text] [Related]
15. Efficacy comparison of medications approved for chronic weight management.
Kumar RB; Aronne LJ
Obesity (Silver Spring); 2015 Apr; 23 Suppl 1():S4-7. PubMed ID: 25900871
[TBL] [Abstract][Full Text] [Related]
16. Current and emerging pharmacotherapies for obesity in Australia.
Hocking S; Dear A; Cowley MA
Obes Res Clin Pract; 2017; 11(5):501-521. PubMed ID: 28818558
[TBL] [Abstract][Full Text] [Related]
17. Fixed-dose combination of phentermine-topiramate for the treatment of obesity.
Halpern B; Faria AM; Halpern A
Expert Rev Clin Pharmacol; 2013 May; 6(3):235-41. PubMed ID: 23656337
[TBL] [Abstract][Full Text] [Related]
18. Combination phentermine and topiramate extended release in the management of obesity.
Alfaris N; Minnick AM; Hopkins CM; Berkowitz RI; Wadden TA
Expert Opin Pharmacother; 2015 Jun; 16(8):1263-74. PubMed ID: 25958964
[TBL] [Abstract][Full Text] [Related]
19. Update on obesity pharmacotherapy.
Bray GA; Ryan DH
Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
[TBL] [Abstract][Full Text] [Related]
20. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
